Staffing is an issue for the clinical lab industry writ large, but rapid growth in demand and quickly changing technology has made liquid biopsies a particularly tricky area.
Last week, readers were most interested in a story about Tempus' offer to buy cancer diagnostic firm Personalis for $1.5 billion.
NEW YORK – Quest Diagnostics raised its full-year 2026 revenue and EPS guidance on Thursday as the company saw solid Q2 growth across its business. The firm said it now expects full-year net revenue ...
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
The firm is developing blood-based early cancer detection tests for a variety of indications, including colorectal cancer and lung cancer.
NEW YORK – Roche on Friday announced that its molecular test for vaginitis has received 510(k) clearance from the US Food and Drug Administration. The PCR-based Cobas BV/CV test uses ...
The IVDR encompasses the firm's ER, PR, and Ki67 testing and completes certification of its overall digital pathology breast suite.
The firm looks to position its Halo lung assay for detecting cancers not found by LDCT and in average-risk populations for which LDCT screening is not currently recommended.
The approval allows the company to offer its PD-L1 IHC 22C3 pharmDx Code SK006 CDx for ovarian and other cancers.
The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.
The second generation test can detect the Bundibugyo strain of the virus that currently poses a threat in the Democratic Republic of the Congo and nearby countries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results